Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Receivables (2019 - 2025)

Cue Biopharma's Receivables history spans 7 years, with the latest figure at $387000.0 for Q3 2025.

  • For Q3 2025, Receivables fell 87.72% year-over-year to $387000.0; the TTM value through Sep 2025 reached $387000.0, down 87.72%, while the annual FY2024 figure was $945000.0, 44.35% down from the prior year.
  • Receivables for Q3 2025 was $387000.0 at Cue Biopharma, down from $532000.0 in the prior quarter.
  • Across five years, Receivables topped out at $3.2 million in Q3 2024 and bottomed at $57000.0 in Q4 2022.
  • The 5-year median for Receivables is $1.0 million (2023), against an average of $1.3 million.
  • The largest annual shift saw Receivables tumbled 98.19% in 2022 before it skyrocketed 2878.95% in 2023.
  • A 5-year view of Receivables shows it stood at $3.1 million in 2021, then tumbled by 98.19% to $57000.0 in 2022, then surged by 2878.95% to $1.7 million in 2023, then tumbled by 44.35% to $945000.0 in 2024, then plummeted by 59.05% to $387000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Receivables are $387000.0 (Q3 2025), $532000.0 (Q2 2025), and $945000.0 (Q4 2024).